Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases
Open Access
- 1 July 2019
- journal article
- research article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 17 (8) , 1533-1540.e2
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor AgentsClinical Gastroenterology and Hepatology, 2016
- Pseudomonas Meningitis During Vedolizumab Therapy for Crohn’s DiseaseAmerican Journal of Gastroenterology, 2015
- Smoking prevalence and its influence on disease course and surgery in Crohn's disease and ulcerative colitisAlimentary Pharmacology & Therapeutics, 2015
- Epidemiology and risk factors for IBDNature Reviews Gastroenterology & Hepatology, 2015
- Risks of Serious Infection or Lymphoma With Anti–Tumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel Disease: A Systematic ReviewClinical Gastroenterology and Hepatology, 2014
- Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBDGut, 2014
- Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancerGut, 2013
- Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's diseaseAnnals of the Rheumatic Diseases, 2013
- A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel DiseaseAmerican Journal of Gastroenterology, 2012
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesThe Lancet, 2007